Cancer Network Podcasts

Andrew Evens, DO, MSc, deputy director for clinical and translational research and medical director of the Clinical Research Office at the UMass Memorial Health Care Cancer Center of Excellence, talks about his research on lymphoma during pregnancy.

We interview Kent Osborne, the moderator of the year in review session. He has been involved with the meeting since its beginning. The international San Antonio Breast Cancer Symposium is unique as it facilitates the interaction of both basic and science researchers and clinicians to combine the efforts of laboratory research and clinical research for better treatment and patient care.

We speak with Dr. Joseph Sparano, professor of medicine and women’s health at the Albert Einstein School of Medicine and associate chairman of the department of oncology at Montefiore Medical Center in New York, about the session he will chair at the ASCO Breast Cancer Symposium.

Dr. Susan O’Brien was one of the presenters at the ASCO 2011 session on therapies for chronic lymphocytic leukemia, in this podcast she gives some highlights of the session and insights into her own work.

We talk with Dr. David Mankoff, professor of radiology, medicine, and bioengineering in the department of radiology at the University of Washington in Seattle. Dr. Mankoff will be one of the co-chairs at the upcoming ASCO session on molecular imaging in cancer clinical trials, and he gives us a preview of what some of the highlights of the session are likely to be, as well as some insights into his own work.

The combination of biomarkers and molecular pathology will aid oncologists in developing targeted treatments for breast cancer, according to Samuel Aparicio, MD, PhD, who will be delivering a presentation on recognizing breast cancer heterogeneity in targeted treatment at the Miami Breast Cancer Conference this week.

The early promise of treating triple-negative and basal-cell breast cancers with poly (ADP-ribose) polymerase (PARP) inhibitors is yet to be realized, according to Lisa A. Carey, MD, who will be delivering a presentation on treatment options for these patients at the Miami Breast Cancer Conference this week.

The discovery of human epidermal growth factor receptor 2 (HER2)-positive breast cancer subtypes is not yet complete, according to Mark D. Pegram, MD, who will be delivering a presentation on the different clinical outcomes of these subtypes at the Miami Breast Cancer Conference this week.

Are genomic profiles refined enough that they should be used routinely to determine which breast cancer patients should receive adjuvant therapy? According to J. Michael Dixon, MD, who will be presenting the contra argument to this question in a debate at the Miami Breast Cancer Conference this week, the answer is: Not yet.

We speak with expert Emily Conant, MD, who says it’s very important to carefully analyze the data and weigh the pros and cons and the risk to benefits that exist within any study. Naturally, because mammography is such a widely used screening tool, it gets quite a bit of scrutiny. But it is all about the data, how it’s sliced and diced.

Clinicians often cite enhanced quality care, patient safety, and increased efficiencies as rationale for implementing electronic medical records. Those are strong reasons for interest in medical software. However, in a climate where reimbursements are falling, the cost and difficulty of EMRs can increasingly seem to be a barrier. We speak with nationally recognized healthcare specialist Marty Neltner to find out.

We speak with Dr. Samuel Silver who elucidates the current trends and therapies for treating various blood cancers.

In this exclusive podcast, nationally regarded healthcare specialist, Marty Neltner, talks about how given the current atmosphere in today's challenging healthcare market, community oncology practices need to be especially alert to future trends, one of which is value over volume.

Listen to internationally regarded oncologist and clinical investigator, Robert J. Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center, discuss the past, present, and future trends in renal cell carcinoma.

In this exclusive ASCO podcast, Andrew J. Armstrong, MD, ScM, assistant professor of medicine and surgery at Duke Comprehensive Cancer Center, addresses the vexing clinical issue of chemotherapy’s limited effectiveness in advanced renal cell carcinoma.

Dr. Debu Tripathy, co-course director for the 27th Annual Miami Breast Cancer Conference sheds light on his presentation, The Role of Maintenance Therapy for Metastatic Breast Cancer, truly a complicated and controversial topic.